Key Takeaways: Optimal Use of JAK Inhibitors in MF and Future Directions in Care
Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.
Patient Scenario 2: A 68-Year-Old Woman With Anemic MF
Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.
Sequencing of JAK Inhibitors in Patients With Myelofibrosis
In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.
Myelofibrosis: Dosing JAK Inhibitors and Managing Adverse Events
Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.
JAK Inhibitors in Patients With Cytopenic Myelofibrosis
A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.
Value of JAK Inhibitors in Myelofibrosis Management
A broader overview of the role that JAK inhibitors play in patients with myelofibrosis and how that role has continued to evolve in the current treatment paradigm.
Patient Scenario 1: A 72-Year-Old Man With Primary Myelofibrosis
Moving on to review the first patient scenario of primary myelofibrosis, panelists elucidate the decisionmaking process when selecting JAK inhibitor therapy.
Myelofibrosis Management: Current Treatment Guidelines
Expert panelists share brief insight on the current NCCN guidelines for selecting treatment in patients with myelofibrosis.
Selecting Transplantation Versus Systemic Therapy in Myelofibrosis
Focused discussion on the factors that help to select patients for stem cell transplantation over systemic therapy in the setting of myelofibrosis.
Evolving Role of Transplantation in Myelofibrosis
A comprehensive discussion on the respective role stem cell transplantation has in the treatment armamentarium for myelofibrosis.
Biomarkers in Myelofibrosis: LDH, BMF, and Triple-Negative Disease
Key opinion leaders in myelofibrosis management reflect on the role of biomarkers in informing treatment selection, even for patients with triple-negative disease.
What is the Role of Cytogenetics/Genomics in Myelofibrosis?
Shared insight from a panel of experts on the current state of cytogenetics in myelofibrosis and how it impacts treatment pathways for patients.
Identifying the Signs and Symptoms of Myelofibrosis
Expert panelists provide an overview of the signs and symptoms indicative of myelofibrosis and consider factors that help to inform prognostication.
Clinical Pearls for Community Oncologists Treating Myelofibrosis
The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.
Unmet Needs in Myelofibrosis Treatment
Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.
Sequencing Treatments for Myelofibrosis
A look at sequencing strategies for myelofibrosis treatments.
Assessing Response to Treatment in Myelofibrosis
Dr Srdan Verstovsek shares how he assesses myelofibrosis treatment response in his clinical practice.
Considering Toxicities when Choosing Appropriate Treatment for Myelofibrosis
Raajit Rampal, MD, explains how he considers safety profiles when deciding on appropriate treatment for myelofibrosis and how he manages toxicities for patients.
Approaches to Switching Treatments for Myelofibrosis
A discussion on when to switch a patient with myelofibrosis to a new JAK inhibitor treatment, and possible strategies for transitioning.
Clinical Scenario: Myelofibrosis Treatment in the Second-Line Setting
John Mascarenhas, MD, presents a clinical scenario of a 73-year-old man with myelofibrosis and a low platelet count.
Treatments for Myelofibrosis Based on Platelet Counts
A panel of experts considers treatment options for patients with myelofibrosis based on platelet counts, while factoring in health insurance barriers.
Therapy Strategies for Primary Myelofibrosis
Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.
Approved Treatments for Myelofibrosis
A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.
Clinical Scenario: Patient with Primary Myelofibrosis
Dr John Mascarenhas presents a patient case scenario of a 68-year-old woman with a common presentation of primary myelofibrosis.
The JAK/STAT Pathway and Myelofibrosis
Raajit Rampal, MD, describes the JAK-STAT pathway and how it’s fundamental to all types of myelofibrosis.
Differences Between Types of Myelofibrosis
Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.
Diagnosis and Risk Stratification of Myelofibrosis
Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.
Optimizing Therapy for Patients With Myelofibrosis
Responses to questions by community hematologists/oncologists regarding optimal ways to diagnose and manage patients with myelofibrosis.
Individualizing Therapy for Patients With Myelofibrosis
Clinical pearls for planning and sequencing therapy for patients with myelofibrosis.
Second-Line Therapy for High-Risk Primary Myelofibrosis
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.